Physician profile
Alison Considine
NPI 1255507158
$81,666.30
in general payments reported to CMS, 2019-2025
11 companies · $75K in 2025
The $75K reported for 2025 was more than what 99% of Anesthesiology providers received nationally (typical 2025 total: $58.09).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $142 · 2020: $55.91 · 2021: $112 · 2022: $106 · 2023: $116 · 2024: $6,097 · 2025: $75K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $48K · Travel and Lodging: $30K · Food and Beverage: $2,853.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $48,250.00 |
| Travel and Lodging | $30,147.55 |
| Food and Beverage | $2,852.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Conmed Corporation | $80,732.98 | 2024-2025 | Airseal, Vcare, Conmed Specimen Retrieval |
| Merck Sharp & Dohme LLC | $499.67 | 2019-2025 | Bridion |
| Janssen Biotech, INC. | $106.76 | 2023-2024 | Tremfya, Stelara, Simponi Aria |
| Ardelyx, INC. | $65.51 | 2024-2025 | Ibsrela |
| Regeneron Healthcare Solutions, INC. | $63.25 | 2022-2025 | Dupixent |
| Abbvie INC. | $49.86 | 2024-2025 | |
| Qol Medical, LLC | $45.16 | 2025 | Sucraid |
| Heron Therapeutics, INC. | $34.81 | 2021-2024 | Aponvie |
| Takeda Pharmaceuticals U.S.A., INC. | $24.85 | 2025 | Entyvio |
| Intercept Pharmaceuticals, INC. | $24.80 | 2024 | |
| Edwards Lifesciences Corporation | $18.65 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alison Considine listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.